Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer-Reference-Cited by-同舟云学术

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer

Published:2016-06-29 Issue:3 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wuntakal Rekha¹,Seshadri Srividya²,Montes Ana³,Lane Geoff⁴

Affiliation:

1. Gynaecological Oncology; Barking, Havering & Redbridge University Hospitals NHS Trust; Romford UK

2. The Centre for Reproductive & Genetic Health; London UK

3. Medical Oncology; Guy's and St Thomas' Hospital NHS Foundation Trust; London UK

4. Gynaecological Oncology; Guy's and St Thomas' Hospital NHS Foundation Trust; London UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference59 articles.

1. A randomised placebo-controlled efficacy and safety study of a sustained release LHRH agonist (Decapeptyl) in patients with advanced ovarian cancer;Currie;Gynecologic Oncology,1994

2. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer;Du Bois;Annals of Oncology 2002,2002

3. Hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer study group;Emons;Cancer,1996

4. A randomized comparison of decapeptyl and tamoxifen as treatment of progressive ovarian cancer;Jager;Gynecological Endocrinology,1993

5. Comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer;Jager;Anticancer Research,1995

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

2. Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2;BMC Cancer;2023-04-06

3. Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer;Frontiers in Oncology;2023-03-10

4. Effects of leuprorelin for the treatment of recurrent gynecological cancer by assessment including self-administered quality-of-life questionnaire;Journal of Obstetrics and Gynaecology Research;2018-08-16